Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK welcomes flu pandemic guidance

GSK welcomes flu pandemic guidance

30th January 2008

GlaxoSmithKline (GSK) has welcomed new guidance released by the European Medicines Agency (EMEA) over the use of antivirals during a possible flu pandemic.

Following new research into viral resistance, the body has recommended that several types of antiviral should be available when preparing for a pandemic.

In particular, the EMEA found that resistance among children was more frequent with the increasing use of Tamiflu (oseltamivir).

However, GSK’s Relenza (zanamivir) was shown to bring about minimal viral resistance, with some viral strains resistant to Tamiflu remaining sensitive to Relenza.

Following the research, GSK has stated its belief that it would be appropriate for Relenza to be stockpiled as part of flu pandemic preparations.

Eddie Gray, president of GSK Pharma Europe, said that the EMEA study highlighted zanamivir’s “important role” in preparing for a potential pandemic.

“As a manufacturer of both antivirals and influenza vaccines, GSK is fully committed to supporting governments in their plans to counter the threat of an influenza pandemic,” he added.

Earlier this month, GSK announced that its once-daily Avamys (fluticasone furoate) nasal spray had been granted marketing authorisation by the European Commission for the treatment of allergic rhinitis.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.